Related Experiment Video
Updated: Jun 9, 2025
14:18
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
1.7K
Cyclosporine-Iinduced Glycosuria
Heng Li Wei1, Ho Sheun Ling Madeline2, Yew Yik Weng2,3
1Department of Dermatology, National Skin Center, National Healthcare Group, Singapore; hengliweires@gmail.com.
Skinmed
|October 21, 2024
Summary
Cyclosporine, an immunosuppressant, can cause glycosuria (glucose in urine) in psoriasis patients, even with normal blood sugar. This side effect is reversible and may necessitate a change in medication.
Area of Science:
- Nephrology
- Dermatology
- Clinical Pharmacology
Background:
- Psoriasis treatment often involves immunosuppressants like cyclosporine.
- Monitoring for adverse effects is crucial during immunosuppressive therapy.
Observation:
- A 42-year-old male with psoriasis developed glycosuria (300 mg/dL) after 18 months of cyclosporine therapy.
- Fasting serum glucose remained normal (5.2 mmol/L), and no urinary tract infection was present.
Findings:
- Cyclosporine, at a reduced dose (100 mg every 2 days), was associated with drug-induced glycosuria.
- The glycosuria resolved spontaneously after dose adjustment and discontinuation of cyclosporine.
Implications:
- This case highlights a potential renal side effect of cyclosporine, specifically isolated glycosuria.
- Clinicians should consider monitoring for glycosuria in patients on cyclosporine, even with normal glycemic control.
- This finding may inform treatment decisions and medication adjustments in patients with psoriasis.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
161
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
161
01:27Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
01:06Oral Hypoglycemic Agents: Glinides
142
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
01:17Oral Hypoglycemic Agents: Sulfonylureas
193
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
193
01:15Hypoglycemia and Glucagon
153
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
153